Claims for Patent: 9,050,322

Summary for Patent: 9,050,322

Title:	Targeted identification of immunogenic peptides
Abstract:	This invention relates generally to identifying peptide sequences involved in antibody binding to any protein for synthesis of vaccine treatments. This novel method allows for a more manageable vaccine peptide discovery and specific generation of unique immunogenic peptides from self-tumor associated proteins and/or foreign proteins from infectious organisms for specific and/or enhanced expression only in the presence of the antibody.
Inventor(s):	Ponniah; Sathibalan (Columbia, MD), Peoples; George E (Fulton, MD), Storrer; Catherine E (Columbia, MD), Flora; Michael (Mt. Airy, MD)
Assignee:	The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. (Bethesda, MD)
Application Number:	13/774,829
Patent Claims:	1. A method for treating a patient with a cancer expressing HER2/neu, the method comprising administering in any order to the patient an immunotherapy consisting of, a therapeutically effective amount of an antibody to a Her2/neu antigen the patient; and a therapeutically effective amount of a peptide vaccine comprising a Her2/neu peptide antigen consisting of the amino acid sequence of SEQ ID NO: 4, as the sole peptide in the vaccine. 2. The method of claim 1, wherein the peptide vaccine is administered before, after or at the same time as administration of the antibody. 3. The method of claim 1, wherein administration of the peptide and the antibody have a synergistic effect on the patient. 4. The method of claim 1, wherein the cancer is breast cancer. 5. The method of claim 4, wherein the antibody is trastuzumab. 6. The method of claim 5, wherein the peptide vaccine is administered after administration of trastuzumab. 7. The method of claim 1, wherein the antibody is trastuzumab. 8. The method of claim 1, wherein the cancer is selected from the group consisting of prostate cancer, ovarian cancer and breast cancer. 9. The method of claim 8, wherein the antibody is trastuzumab. 10. The method of claim 9, wherein the peptide vaccine is administered after administration of trastuzumab. 11. A method for inducing an immune response to HER2/neu in a patient with a cancer expressing HER2/neu, the method consisting of administering to the patient in any order, (a) an antibody that binds to the Her2/neu antigen; and (b) a peptide vaccine comprising a HER2/neu peptide antigen consisting of the amino acid sequence of SEQ ID NO: 4, as the sole peptide in the vaccine. 12. The method of claim 11, wherein the antibody is trastuzumab. 13. The method of claim 11, wherein the cancer is selected from the group consisting of prostate cancer, ovarian cancer and breast cancer. 14. The method of claim 13, wherein the antibody is trastuzumab. 15. The method of claim 11, wherein the cancer is breast cancer. 16. The method of claim 15, wherein the antibody is trastuzumab.

Details for Patent 9,050,322

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	09/25/1998		2025-09-08
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	02/10/2017		2025-09-08
Genentech, Inc.	HERCEPTIN HYLECTA	trastuzumab and hyaluronidase-oysk	Injection	761106	02/28/2019		2025-09-08